{
    "clinical_study": {
        "@rank": "139497", 
        "acronym": "iCHF", 
        "arm_group": [
            {
                "arm_group_label": "Iron", 
                "arm_group_type": "Active Comparator", 
                "description": "ferric carboxymaltose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Sodium chloride 0.9%"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis to be tested is whether treatment with intravenous iron (ferric\n      carboxymaltose) will improve left-ventricular ejection fraction in patients with heart\n      failure and iron deficiency as determined by cardiac magnetic resonance imaging."
        }, 
        "brief_title": "Iron in Congestive Heart Failure", 
        "condition": [
            "Heart Failure", 
            "Iron Deficiency", 
            "Anemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Heart Failure", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Congestive heart failure\n\n          -  At least 18 years of age\n\n          -  Iron deficiency\n\n          -  Dyspnea class II or III according to New York Heart Association\n\n          -  Left-ventricular ejection fraction \u2264 45%\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to any of the products to be administered during dosing\n\n          -  Immediate need of transfusion\n\n          -  Patients presenting with an active infection\n\n          -  Thalassaemia\n\n          -  Other forms of microcytic anemia not caused by iron deficiency\n\n          -  History of acquired iron overload\n\n          -  Need for revascularization, ST-segment elevation myocardial infarction or\n             Non-ST-segment elevation myocardial infarction during the past 3 months (at time of\n             randomization)\n\n          -  Women who are pregnant or of childbearing age and not using medically acceptable\n             effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837082", 
            "org_study_id": "iCHF_D.3874", 
            "secondary_id": "2012-001134-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iron", 
                "intervention_name": "ferric carboxymaltose", 
                "intervention_type": "Drug", 
                "other_name": "Ferinject"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sodium chloride 0.9%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ferric Compounds"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart Failure", 
            "Iron Deficiency", 
            "Anemia", 
            "Ferric Carboxymaltose"
        ], 
        "lastchanged_date": "April 17, 2013", 
        "location": [
            {
                "contact": {
                    "email": "vbrandenburg@ukaachen.de", 
                    "last_name": "Vincent Brandenburg, MD", 
                    "phone": "+49-241-8085709"
                }, 
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "University of Aachen"
                }, 
                "investigator": {
                    "last_name": "Vincent Brandenburg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mahir.karakas@uniklinik-ulm.de", 
                    "last_name": "Mahir Karakas, MD", 
                    "phone": "+49-731-50045075"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "University of Ulm"
                }, 
                "investigator": {
                    "last_name": "Mahir Karakas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Placebo-controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients With Congestive Heart Failure", 
        "overall_contact": {
            "email": "mahir.karakas@uniklinik-ulm.de", 
            "last_name": "Mahir Karakas, MD", 
            "phone": "+49-731-50045075"
        }, 
        "overall_official": {
            "affiliation": "University of Ulm", 
            "last_name": "Mahir Karakas, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint of the study is the change from baseline to week 12 in left-ventricular ejection fraction as determined by cardiac magnetic resonance imaging.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837082"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Ulm", 
            "investigator_full_name": "Dr. Mahir Karakas", 
            "investigator_title": "Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Ulm", 
        "sponsors": {
            "collaborator": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Ulm", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}